Malaysia: digestives & intestinal remedies revenue growth 2019-2029

The revenue change in the 'Digestives & Intestinal Remedies' segment of the otc pharmaceuticals market in Malaysia was forecast to continuously decrease between 2024 and 2029 by in total 1.5 percentage points. According to this forecast, in 2029, the indicator will have decreased for the fourth consecutive year to 3.93 percent.

Find other key market indicators concerning the revenue and average revenue per user (ARPU).

The Statista Market Insights cover a broad range of additional markets.

Revenue growth of the digestives & intestinal remedies market in Malaysia from 2019 to 2029

Characteristic	Revenue growth
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

Definition:
The Digestives and Intestinal Remedies market comprises over-the-counter natural and synthetic digestive agents and remedies against gastrointestinal complaints. Digestives include preparations in the form of pills, powder, capsules, liquids, solutions, suspensions, drops and suppositories. Not included are prescription medicines, preparations that are against the state law or are not explicit digestive drugs (e.g. painkillers). Among the top-selling digestives are Perenterol, Iberogast, Dulcolax and Buscopan Plus. It includes both products which are exclusively sold in pharmacies and products which can be purchased elsewhere. Sales by hospitals are not included.

Additional information:
The Digestives and Intestinal Remedies market comprises revenues, average revenue per capita. Sales channels show online and offline revenue. Revenues include VAT. The market only displays B2C revenues, hence B2B and B2G revenues are not included.
For more information on the data displayed, use the info button next to the boxes.

Citation formats